PLSMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Pulsenmore Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 30, 2026

$1.78−0.09 (-4.81%)

Close on Oct 19, 2026

Pulsenmore Ltd. income statement

AnnualQuarterlyTTM

ILS USD

Millions of ILS, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	40	9.66	6.19
Cost of Revenue	6.34	6.08	3.99
Gross Profit	34	3.58	2.20
Research & Development	17	20	31
Selling & Marketing	12	10	9.43
Interest Expense	7.23	0.54	16
Interest & Investment Income	3.54	5.96	13
Pretax Income	-16	-37	-58
Income Tax Expense	0.00	-0.06	0.13
Net Income incl. Noncontrolling Interests	-16	-37	-59
EPS (Basic)(per share)	2.46	5.76	9.12
EPS (Diluted)(per share)	2.46	5.76	9.12
Shares Outstanding (Basic, Weighted)(shares)	6.44	6.40	6.40
Shares Outstanding (Diluted, Weighted)(shares)	6.44	6.40	6.40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 84.2%
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.84
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 99.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.